A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects

Climacteric

Volumn 1, Issue 2, 1998, Pages 112-123

  O'Connell, D ^a,c   Robertson, J ^a   Henry, D ^a   Gillespie, W ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

Bone mass; Efficacy; EStrogen therapy; Hormone replacement rherapy; Meta analysis; Randomized controlled trials

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; ESTROGEN THERAPY; FEMALE; HIP FRACTURE; HUMAN; METHODOLOGY; MIDDLE AGED; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPINE FRACTURE; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 0032098315     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139809085526     Document Type: Article

References (58)

1. Henry D, Robertson J, O'Connell D, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women: I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998;1:92-111
2. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. San Diego: Academic Press, 1985
3. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88
4. Riis BJ, Nilas L, Christiansen C. Does calcium potentiate the effect of estrogen therapy on postmenopausal bone loss? Bone Miner 1987;2:1-9
5. Haines CJ, Chung TKH, Leung PC, Hsu SYC, Leung DHY. Calcium supplementation and bone mineral density in postmenopausal women using estrogen replacement therapy. Bone 1995;16:529-31
6. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991;90:171-8
7. Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992;79:202-10
8. Marslew U, Riis BJ, Christiansen C. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur J Clin Invest 1991;21:601-7
9. Dören M, Reuther G, Minne HW, Schneider HPG. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995;173:1446-51
10. Palacios S, Menéndez C, Jurado AR, Vargas JC. Effects of percutaneous oestradiol versus oral oestrogens on bone density. Maturitas 1995;20:209-13
11. Aloia JF, Vaswani A, Yeh JK, Ross PL, Plaster E, Dilmanian FA. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994;120:97-103
12. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995;10:697-703
13. Castelo-Branco C, Pons F, Gonzalez-Merlo J. Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas 1993;16:133-7
14. Meschia M, Brincat M, Barbacini P, Crossignani PG, Albisetti W. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993;53:17-20
15. Castelo-Branco G, Martinez de Osaba MJ, Pons F, Gonzalez-Merlo J. The effect of hormone replacement therapy on postmenopausal bone loss. Eur J Obstet Gynecol Reprod Biol 1992;44:131-6
16. Harris ST, Genant HK, Baylink DJ, Gallagher JC, Karp SK, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Int Med 1991;151:1980-4
17. Isaia G, Campagnoli C, Mussetta M, Massobrio M, Salamano G, Gallo M, et al. Calcitonin and lumbar bone mineral content during oestrogenprogestogen administration in post-menopausal women. Maturitas 1989;11:287-94
18. Riis BJ, Johansen J, Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas 1988;10:51-8
19. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med 1987;316:173-7
20. Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982;97:699-705
21. Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. Br Med J Clin Res 1988;296:1150-2
22. Riis BJ, Jensen J, Christiansen C. Cyproterone acetate, an alternative to gestagen in post-menopausal estrogen/gestagen therapy. Clin Endocrinol 1987;26:327-34
23. Ettinger B, Genant HK, Steiger P, Madvig P. Lowdosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992;166:479-88
24. Adami S, Suppi R, Bertoldo F, Rossini M, Residori M, Maresca V, et al. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 1989;7:79-86
25. Gambacciani M, Spinetti A, Taponeco F, Ciaponi M, Cima GP, Teti GC, et al. Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy. Gynecol Endocrinol 1995;9:131-5
26. Cagnacci A, Melis GB, Soldani R, Paoletti AM, Gambacciani M, Spinetti A, et al. Neuroendocrine and clinical effects of transdermal 17β-estradiol in postmenopausal women. Maturitas 1991;13:283-96
27. Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977;87:649-55
28. Christensen MS, Hagen C, Christiansen C, Transbøl I. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873-9
29. Christiansen C, Christensen MS, Rødbro P, Hagen C, Transbøl I. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 1981;11:305-9
30. Finn Jensen G, Christiansen C, Transbøl I. Treatment of postmenopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitȧmin D3 and calcium. Clin Endocrinol Oxf 1982;16:515-24
31. Lindsay R, Hart DM, Purdie D, Ferguson MM, Clark AS, Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978;54:193-5
32. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759-63
33. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9
34. Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980;280:1207-9
35. Horsman A, Gallagher JC, Simpson M, Nordin BE. Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J 1977;2:789-92
36. Christiansen C, Riis BJ. 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836-41
37. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowitz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9
38. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-5
39. Civitelli R, Agnusdei D, Nardi P, Zacchei F, Avioli LV, Gennari C. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-1 α-hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int 1988;42:77-86
40. Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991;13:155-62
41. Agnusdei D, Civitelli R, Camporeale A, Gennari C. Calcitonin and estrogens. J Endocrinol Invest 1990;13:625-30
42. Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta Endocrinol (Copenh) 1990;123:14-18
43. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;336:265-9
44. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman M. Estrogen replacement therapy. I. Ten year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979;53:277-81
45. 3 accelerate spinal bone loss? A controlled therapeutic trial in 70 year old women. Clin Orthopaed Rel Res 1985;1992:215-21
46. MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993;159:102-6
47. Perrone G, Falaschi P, Capri O, Pastore R, Galoppi P, D'Urso R, et al. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil 1994;39:202-7
48. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipidlipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529-37
49. Birkenhäger JC, Erdtsieck RJ, Zeelenberg J, van Kuik C, van Veen LCP, Birkenhäger-Frenkel DH, et al. Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis? Bone Miner 1992;18:251-65
50. Garnett T, Studd J, Watson N, Savvas M, Leather A. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Obstet Gynecol 1992;79:968-72
51. Da vis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36
52. Barlow DH, Abdalla HI, Roberts AD, Al Azzawi F, Leggate I, Hart DM. Long-term hormone implant therapy - hormonal and clinical effects. Obstet Gynecol 1986;67:321-5
53. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5
54. Kreiger N, Kelsey JL, Holford TR, O'Connor T. An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol 1982;116:141-8
55. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fractures. Br Med J 1992;305:1124-8
56. Windeler J, Lange S. Events per person year - a dubious concept. Br Med J 1995;310:454-6
57. Barrett-Connor E. Post-menopausal estrogen and prevention bias. Ann Intern Med 1991;115:455-6
58. The Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density. Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc 1996;276:1389-96